Serynth Milia Remover

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of milia, which are small skin bumps. It aids in the exfoliation of dead skin cells and helps to smooth skin texture.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Healthcare professionals are advised to cleanse and dry the affected skin area thoroughly prior to application. A thin layer of the product should be applied directly onto the milia (skin bumps) once or twice daily, depending on the severity of the condition and patient response. The product should be gently massaged into the skin until fully absorbed.

For optimal results, consistent use of the product for a duration of 4 weeks is recommended.

Contraindications

Use is contraindicated in the following situations:

• Do not use if the condition worsens or does not improve within 4 weeks.

• Do not use if severe redness, burning, or swelling occurs.

• If pregnant or breastfeeding, consult a healthcare professional before use.

• Avoid contact with eyes, lips, and mucous membranes; if contact occurs, rinse thoroughly with water.

• Do not apply to broken, irritated, or sunburned skin, as excessive drying or peeling may occur. Discontinue use if severe irritation develops.

Warnings and Precautions

For external use only.

Healthcare professionals should advise patients to keep this product out of reach of children to prevent accidental ingestion or misuse. It is imperative that patients are instructed not to use the product if their condition worsens or does not improve within four weeks. Additionally, they should seek medical attention if they experience severe redness, burning, or swelling.

In the case of pregnancy or breastfeeding, patients are encouraged to consult a healthcare professional prior to use to ensure safety for both the mother and child.

Should any severe irritation develop during the use of this product, it is essential for patients to discontinue use immediately and contact their healthcare provider for further guidance.

Side Effects

Patients using this product should be aware that it is intended for external use only. Care should be taken to avoid contact with the eyes, lips, and mucous membranes; in the event of contact, the affected area should be rinsed thoroughly with water. The product should not be applied to broken, irritated, or sunburned skin, as this may lead to excessive drying or peeling.

In clinical use, if severe irritation develops, patients are advised to discontinue use immediately. Additionally, patients should consult a healthcare professional if their condition worsens or does not improve within four weeks of use. They should also seek medical advice if they experience severe redness, burning, or swelling. Pregnant or breastfeeding individuals are encouraged to consult a health professional prior to using this product.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Serynth Milia Remover (salicylic acid 1% milia remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. It is essential to ensure that the medication is stored safely to prevent accidental ingestion or misuse.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure safe use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

There is no specific information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

There is currently no specific information available regarding overdosage for this medication. In the absence of documented overdosage data, healthcare professionals are advised to exercise caution and monitor patients closely for any unusual symptoms or adverse effects that may arise following administration.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Continuous monitoring of vital signs and clinical status is essential to ensure patient safety.

Healthcare professionals should also consider consulting a poison control center or relevant toxicology resources for guidance on management strategies tailored to the specific circumstances of the overdosage event.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. Patients who are pregnant or breastfeeding should be encouraged to consult a healthcare professional before using the product to ensure safety for themselves and their child.

It is important for patients to monitor their condition closely. They should be informed that if their condition worsens or does not improve within four weeks, or if they experience severe redness, burning, or swelling, they should seek medical advice promptly.

Patients should be cautioned to avoid contact with the eyes, lips, and mucous membranes. In the event of contact, they should rinse the area thoroughly with water to minimize irritation. Additionally, the medication should not be applied to broken, irritated, or sunburned skin to prevent further complications.

Patients should be made aware that excessive drying or peeling of the skin may occur with use. If they experience severe irritation, they should discontinue use and consult their healthcare provider for further guidance.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain its integrity. It should be stored at room temperature, away from direct light to prevent degradation. Additionally, it is essential to keep the product out of reach of children to ensure safety.

Additional Clinical Information

The product is administered topically, with a recommendation to apply a thin layer directly onto the milia (skin bumps) once or twice daily, as needed. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Serynth Milia Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)